Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10138302
APP PUB NO 20140212417A1
SERIAL NO

14345702

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ABLYNX N.V.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
De, Bruyn Steven Baal, BE 2 24
Holz, Josefin-Beate Munich, DE 7 33
Rossenu, Stefaan Lovendegem, BE 2 24
Sargentini-Maier, Maria Laura Brussels, BE 2 35
Yalkinoglu, Özkan Wuppertal, DE 3 27

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 27, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 27, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00